Recently, Boshuizen et al. also demonstrated the role of another AXL-targeting antibody–drug conjugate (Enapotamab vedotin) in potentiating anti-PD-1 (pembrolizumab) therapy in melanoma and lung cancer models resistant to immunotherapy. This evidence concerns the gene AXL and lung carcinoma.